The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

to cover MenABCWY groups. Pfizer's shot is also approved as a two-dose series administered six months apart. With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts, the company confirmed ...

Cespedes covers the Healthcare sector, focusing on stocks such as Sanofi, Roche Holding AG, and Genmab. Currently, the analyst consensus on GlaxoSmithKline is a Hold with an average price target ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

On this front GSK scores very highly, with dividend cover standing at 2.6 times and 2.7 times for 2025 and 2026 respectively. The next stage is to consider the firm’s balance sheet. A sturdy ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...